EGFR and non-small cell lung carcinoma: Two previous randomized studies, the JO25567 and NEJ026 trials, which mainly involved Japanese patients, have demonstrated PFS benefit of erlotinib plus bevacizumab compared to erlotinib monotherapy in the front-line treatment of advanced NSCLC with sensitizing EGFR mutation9,10.